Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interim Postmarket Data Release May Compromise Trials – FDA Panel

This article was originally published in The Gray Sheet

Executive Summary

Members of FDA's Neurological Devices Panel questioned the wisdom of asking sponsors to present interim results of ongoing post-approval trials during a meeting Jan. 26
Advertisement

Related Content

CMS Proposes National Noncoverage Of VNS Therapy For Depression
CMS Proposes National Noncoverage Of VNS Therapy For Depression
Neuronetics Anti-Depression Device Not Equivalent To Shock Therapy – Panel
Compliance With Post-Approval Commitments Goes Public On CDRH Web Site
Compliance With Post-Approval Commitments Goes Public On CDRH Web Site
Panel Deems Drug-Eluting Stents Safe For On-Label Use, But Wants More Data
Cyberonics Seeks Coverage For Anti-Depression Implant In Select Patients
Advertisement
UsernamePublicRestriction

Register

MT024461

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel